中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 5
May  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(5): 975-981

Efficacy and safety of anti-PD-1 monoclonal antibody combined with sorafenib or lenvatinib in treatment of patients with Child-Pugh class B unresectable hepatocellular carcinoma

DOI: 10.12449/JCH240517

  • Department of Oncology，Beijing Ditan Hospital，Capital Medical University，Beijing 100015，China

Research funding:

Capital Health Development Research Project (2022-2-2175)

More Information
  • Corresponding author: CHEN Jinglong， dingxiaoyan198111@163.com （ORCID： 0000-0003-1640-7115）
  • Received Date: 2023-09-19
  • Accepted Date: 2023-10-18
  • Published Date: 2024-05-25
    Abstract
  •   Objective  To investigate the safety and efficacy of tyrosine kinase inhibitors combined with immune checkpoint inhibitors in the treatment of patients with Child-Pugh class B unresectable hepatocellular carcinoma （uHCC）.  Methods  A total of 96 patients with Child-Pugh class B uHCC who were admitted to Beijing Ditan Hospital， Capital Medical University， from December 31， 2020 to March 30， 2023 were enrolled as subjects， among whom 63 patients receiving lenvatinib combined with programmed death-1 （PD-1） inhibitor were enrolled as L group and 33 patients receiving sorafenib combined with PD-1inhibitor were enrolled as S group. The primary endpoint was objective response rate （ORR）， and secondary endpoints included time to progression （TTP）， overall survival （OS）， toxicity， drug withdrawal rate， and dose adjustment rate. The The independent-samples t test was used for comparison of normally distributed continuous data between two groups， and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups； the chi-square test was used for comparison of categorical data between two groups. Survival curves were plotted， and the Kaplan-Meier method was used to calculate the survival rate of patients in both groups， while the Log-rank test was used for comparison between the two groups. The Cox regression model was used to calculate hazard ratio （HR） and its 95% confidence interval （CI） and perform the multivariate analysis of influencing factors for prognosis.  Results  Among the 96 patients with uHCC， 55 （57.3%） had Child-Pugh class B （7 points） uHCC and 41 （42.7%） had Child-Pugh class B （8—9 points） uHCC. The L group had a significantly higher ORR than the S group （46.0% vs 15.2%， P=0.003）， and there were no significant differences between the L group and the S group in median TTP （6.6 months vs 3.5 months， P=0.48） or OS （13.8 months vs 13.2 months， P=0.95）. There was no significant difference in median TTP between the patients with Child-Pugh class B （7 points） uHCC and those with Child-Pugh class B （8—9 points） uHCC （6.6 months vs 4.8 months， P=0.35）， while there was a significant difference in OS between these two groups of patients （14.5 months vs 8.8 months， P=0.045）. The multivariate analysis showed that ORR was a protective factor for both TTP （HR=0.18， 95%CI： 0.09 ‍—‍ 0.36， P<0.001） and OS （HR=0.20， 95%CI： 0.09 ‍—‍ 0.43， P<0.001）. There were no significant differences between the L group and the S group in the overall incidence rate of adverse reactions （98.4% vs 97.0%） and the incidence rate of grade≥3 adverse reactions （68.3% vs 63.6%）， and there were also no significant differences between the two groups in dose adjustment rate （84.8% vs 70.2%） and drug withdrawal rate （56.1% vs 72.7%）.  Conclusion  Compared with the regimen of sorafenib combined with PD-1 inhibitor， the regimen of lenvatinib combined with PD-1 inhibitor can improve the ORR of patients with Child-Pugh class B uHCC， with similar prognosis and safety profile between the two groups.

     

    • FullText(HTML)
  • loading
    • References(28)
  • [1]
    MITTAL S, EL-SERAG HB, SADA YH, et al. Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease[J]. Clin Gastroenterol Hepatol, 2016, 14( 1): 124- 131. e 1. DOI: 10.1016/j.cgh.2015.07.019.
    [2]
    CHAPIN WJ, HWANG WT, KARASIC TB, et al. Comparison of nivolumab and sorafenib for first systemic therapy in patients with hepatocellular carcinoma and Child-Pugh B cirrhosis[J]. Cancer Med, 2023, 12( 1): 189- 199. DOI: 10.1002/cam4.4906.
    [3]
    MARRERO JA, KUDO M, VENOOK AP, et al. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study[J]. J Hepatol, 2016, 65( 6): 1140- 1147. DOI: 10.1016/j.jhep.2016.07.020.
    [4]
    MCNAMARA MG, SLAGTER AE, NUTTALL C, et al. Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma-a meta-analysis[J]. Eur J Cancer, 2018, 105: 1- 9. DOI: 10.1016/j.ejca.2018.09.031.
    [5]
    CHOI WM, LEE DB, SHIM JH, et al. Effectiveness and safety of nivolumab in child-pugh B patients with hepatocellular carcinoma: A real-world cohort study[J]. Cancers(Basel), 2020, 12( 7): 1968. DOI: 10.3390/cancers12071968.
    [6]
    OGUSHI K, CHUMA M, UOJIMA H, et al. Safety and efficacy of lenvatinib treatment in child-pugh A and B patients with unresectable hepatocellular carcinoma in clinical practice: A multicenter analysis[J]. Clin Exp Gastroenterol, 2020, 13: 385- 396. DOI: 10.2147/CEG.S256691.
    [7]
    KUDO M, MATILLA A, SANTORO A, et al. CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis[J]. J Hepatol. 2021, 75( 3): 600- 609. DOI: 10.1016/j.jhep.2021.04.047.
    [8]
    FINN RS, QIN SK, IKEDA M, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma[J]. N Engl J Med, 2020, 382( 20): 1894- 1905. DOI: 10.1056/NEJMoa1915745.
    [9]
    KUDO M, FINN RS, QIN SK, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial[J]. Lancet, 2018, 391( 10126): 1163- 1173. DOI: 10.1016/S0140-6736(18)30207-1.
    [10]
    FAN J, GAO Q. Immunotherapy for hepacellular carcinoma: where there is hope, there is brightness[J]. Chin J Dig Surg, 2022, 21( 2): 199- 204. DOI: 10.3760/cma.j.cn115610-20220215-00080.

    樊嘉, 高强. 肝癌的免疫治疗:有希望便是光明[J]. 中华消化外科杂志, 2022, 21( 2): 199- 204. DOI: 10.3760/cma.j.cn115610-20220215-00080.
    [11]
    General Office of National Health Commission. Standard for diagnosis and treatment of primary liver cancer(2022 edition)[J]. J Clin Hepatol, 2022, 38( 2): 288- 303. DOI: 10.3969/j.issn.1001-5256.2022.02.009.

    国家卫生健康委办公厅. 原发性肝癌诊疗指南(2022年版)[J]. 临床肝胆病杂志, 2022, 38( 2): 288- 303. DOI: 10.3969/j.issn.1001-5256.2022.02.009.
    [12]
    MISCHEL AM, ROSIELLE DA. Eastern cooperative oncology group performance status#434[J]. J Palliat Med, 2022, 25( 3): 508- 510. DOI: 10.1089/jpm.2021.0599.
    [13]
    LLOVET JM, LENCIONI R. mRECIST for HCC: Performance and novel refinements[J]. J Hepatol, 2020, 72( 2): 288- 306. DOI: 10.1016/j.jhep.2019.09.026.
    [14]
    SEYMOUR L, BOGAERTS J, PERRONE A, et al. iRECIST: Guidelines for response criteria for use in trials testing immunotherapeutics[J]. Lancet Oncol, 2017, 18( 3): e143- e152. DOI: 10.1016/s1470-2045(17)30074-8.
    [15]
    US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events(CTCAE), Version 5.0. 2017. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_5.0 https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_5.0
    [16]
    ABOU-ALFA GK, AMADORI D, SANTORO A, et al. Safety and efficacy of sorafenib in patients with hepatocellular carcinoma(HCC) and child-pugh A versus B cirrhosis[J]. Gastrointest Cancer Res, 2011, 4( 2): 40- 44.
    [17]
    KØSTNER AH, SORENSEN M, OLESEN RK, et al. Sorafenib in advanced hepatocellular carcinoma: A nationwide retrospective study of efficacy and tolerability[J]. Sci World J, 2013, 2013: 931972. DOI: 10.1155/2013/931972.
    [18]
    XIE ER, YEO YH, SCHEINER B, et al. Immune checkpoint inhibitors for child-pugh class B advanced hepatocellular carcinoma: A systematic review and meta-analysis[J]. JAMA Oncol, 2023, 9( 10): 1423- 1431. DOI: 10.1001/jamaoncol.2023.3284.
    [19]
    FINN RS, KUDO M, MERLE P, et al. LBA34 Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line(1L) therapy for advanced hepatocellular carcinoma(aHCC)[J]. Ann Oncol, 2022, 33: S1401. DOI: 10.1016/j.annonc.2022.08.031.
    [20]
    QIN SK, CHAN SL, GU SZ, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma(CARES-310): A randomised, open-label, international phase 3 study[J]. Lancet, 2023, 402( 10408): 1133- 1146. DOI: 10.1016/S0140-6736(23)00961-3.
    [21]
    REN ZG, XU JM, BAI YX, et al. Sintilimab plus a bevacizumab biosimilar(IBI305) versus sorafenib in unresectable hepatocellular carcinoma(ORIENT-32): A randomised, open-label, phase 2-3 study[J]. Lancet Oncol, 2021, 22( 7): 977- 990. DOI: 10.1016/S1470-2045(21)00252-7.
    [22]
    WU CJ, LEE PC, HUNG YW, et al. Lenvatinib plus pembrolizumab for systemic therapy-naïve and-experienced unresectable hepatocellular carcinoma[J]. Cancer Immunol Immunother, 2022, 71( 11): 2631- 2643. DOI: 10.1007/s00262-022-03185-6.
    [23]
    XU JM, SHEN J, GU SZ, et al. Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma(RESCUE): A nonrandomized, open-label, phase II trial[J]. Clin Cancer Res, 2021, 27( 4): 1003- 1011. DOI: 10.1158/1078-0432.CCR-20-2571.
    [24]
    TSUCHIYA K, KUROSAKI M, SAKAMOTO A, et al. The real-world data in Japanese patients with unresectable hepatocellular carcinoma treated with lenvatinib from a nationwide multicenter study[J]. Cancers(Basel), 2021, 13( 11): 2608. DOI: 10.3390/cancers13112608.
    [25]
    KUO HY, CHIANG NJ, CHUANG CH, et al. Impact of immune checkpoint inhibitors with or without a combination of tyrosine kinase inhibitors on organ-specific efficacy and macrovascular invasion in advanced hepatocellular carcinoma[J]. Oncol Res Treat, 2020, 43( 5): 211- 220. DOI: 10.1159/000505933.
    [26]
    CASADEI GARDINI A, PUZZONI M, MONTAGNANI F, et al. Profile of lenvatinib in the treatment of hepatocellular carcinoma: Design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials[J]. Onco Targets Ther, 2019, 12: 2981- 2988. DOI: 10.2147/OTT.S192572.
    [27]
    PFISTER D, NÚÑEZ NG, PINYOL R, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC[J]. Nature, 2021, 592( 7854): 450- 456. DOI: 10.1038/s41586-021-03362-0.
    [28]
    RIMINI M, RIMASSA L, UESHIMA K, et al. Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: An international propensity score matching analysis[J]. ESMO Open, 2022, 7( 6): 100591. DOI: 10.1016/j.esmoop.2022.100591.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(5)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (369) PDF downloads(54) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return